JP2023505255A5 - - Google Patents

Info

Publication number
JP2023505255A5
JP2023505255A5 JP2022533510A JP2022533510A JP2023505255A5 JP 2023505255 A5 JP2023505255 A5 JP 2023505255A5 JP 2022533510 A JP2022533510 A JP 2022533510A JP 2022533510 A JP2022533510 A JP 2022533510A JP 2023505255 A5 JP2023505255 A5 JP 2023505255A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ophthalmic pharmaceutical
months
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022533510A
Other languages
English (en)
Japanese (ja)
Other versions
JP7833399B2 (ja
JP2023505255A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063218 external-priority patent/WO2021113580A1/en
Publication of JP2023505255A publication Critical patent/JP2023505255A/ja
Publication of JP2023505255A5 publication Critical patent/JP2023505255A5/ja
Priority to JP2025117830A priority Critical patent/JP2025160247A/ja
Application granted granted Critical
Publication of JP7833399B2 publication Critical patent/JP7833399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022533510A 2019-12-05 2020-12-04 眼科用医薬組成物 Active JP7833399B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117830A JP2025160247A (ja) 2019-12-05 2025-07-14 眼科用医薬組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944074P 2019-12-05 2019-12-05
US62/944,074 2019-12-05
US202063077196P 2020-09-11 2020-09-11
US63/077,196 2020-09-11
PCT/US2020/063218 WO2021113580A1 (en) 2019-12-05 2020-12-04 Ophthalmic pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117830A Division JP2025160247A (ja) 2019-12-05 2025-07-14 眼科用医薬組成物

Publications (3)

Publication Number Publication Date
JP2023505255A JP2023505255A (ja) 2023-02-08
JP2023505255A5 true JP2023505255A5 (https=) 2023-12-05
JP7833399B2 JP7833399B2 (ja) 2026-03-19

Family

ID=74104179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533510A Active JP7833399B2 (ja) 2019-12-05 2020-12-04 眼科用医薬組成物
JP2025117830A Withdrawn JP2025160247A (ja) 2019-12-05 2025-07-14 眼科用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117830A Withdrawn JP2025160247A (ja) 2019-12-05 2025-07-14 眼科用医薬組成物

Country Status (14)

Country Link
US (1) US20230026577A1 (https=)
EP (1) EP4069195A1 (https=)
JP (2) JP7833399B2 (https=)
KR (1) KR20220128619A (https=)
CN (1) CN115397392A (https=)
AU (1) AU2020398224B2 (https=)
BR (1) BR112022010871A2 (https=)
CA (1) CA3160484A1 (https=)
CL (1) CL2022001463A1 (https=)
CO (1) CO2022009260A2 (https=)
IL (1) IL293541A (https=)
MX (1) MX2022006776A (https=)
TW (1) TWI845795B (https=)
WO (1) WO2021113580A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300628A (en) * 2020-09-10 2023-04-01 Vanda Pharmaceuticals Inc Methods for the treatment of cyclic diseases or conditions-PDE IV
HU231668B1 (hu) * 2021-12-28 2025-06-28 Semmelweis Egyetem 60% Szemcsepp készítmény
US20250073125A1 (en) * 2023-09-06 2025-03-06 Opus Life Sciences, Llc High ph formulations and kits
WO2025179141A1 (en) 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease
KR20260048121A (ko) * 2024-10-02 2026-04-09 주식회사 대웅테라퓨틱스 개선된 안정성 및 투약 편의성을 갖는 레바미피드를 포함하는 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
CN101537172B (zh) 2008-08-14 2010-06-30 温州医学院 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法
CN101690712B (zh) 2009-08-25 2011-06-15 武汉武药科技有限公司 一种西他沙星滴眼剂及其制备方法
US20110178147A1 (en) 2009-10-20 2011-07-21 Allergan, Inc. Compositions and methods for controlling pupil dilation
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
CN102988280B (zh) 2012-10-08 2014-03-19 新乡医学院 一种加雷沙星滴眼剂
CN109481392B (zh) * 2015-09-02 2021-12-24 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
WO2017083799A1 (en) * 2015-11-13 2017-05-18 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
MX383072B (es) * 2015-12-24 2025-03-13 Univ California Reguladores del cftr y métodos para su uso
US20180236077A1 (en) 2017-02-21 2018-08-23 Avedro, Inc. Formulations for eye treatments
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物

Similar Documents

Publication Publication Date Title
JP2023505255A5 (https=)
ES2381672T3 (es) Preparación en solución acuosa que comprende un antibiótico aminoglicósido y bromfenaco
KR102607126B1 (ko) 안과용 조성물
DE3872029T2 (de) Rektal absorbierbare form von l-dopa.
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
JP2017002035A5 (https=)
JP2017514924A5 (https=)
CN102014618A (zh) 微乳剂型杀菌组合物
JP2024040421A5 (https=)
CN108184891A (zh) 一种杀菌剂乳液及其制备方法
CN103608000B (zh) 含有透明质酸或其盐以及丙二醇的滴眼液
CN103348967B (zh) 一种用于家禽人工授精的精液稀释液及其使用方法
JP5922609B2 (ja) 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物
JP2024504980A (ja) 点眼組成物
JP4189223B2 (ja) ミノキシジル配合液剤組成物
CN115137699B (zh) 一种增效防腐的右美托咪定鼻喷剂
CN102215819B (zh) 具有相对低的离子强度的药物组合物
EP3829535B1 (en) Compositions for the prevention and treatment of cutaneous affections
CN100494206C (zh) 高负载草甘膦盐稳定液体
CN104430552A (zh) 一种池塘杀菌药物配方
US2132351A (en) Stable aqueous solutions of subtances having an anesthetic effect
CN117838628B (zh) 一种地夸磷索钠滴眼液及其制备方法
WO2013047373A1 (ja) 亜塩素酸塩を含有する水性製剤
WO2015046281A1 (ja) 安定化された2-アミノ-3-(4-ブロモベンゾイル)フェニル酢酸含有水性組成物
RU2011130552A (ru) Композиции местных глазных растворов для доставки эффективных концентраций активного агента в задний сегмент глаза